Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

cerebral amyloid angiopathy

- PMLiVE

Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term

The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark

- PMLiVE

Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s

Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients

- PMLiVE

Lilly and Indiana University collaborate to expand clinical trial access

The five-year agreement includes a focus on R&D for Alzheimer’s disease

- PMLiVE

Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

While the trials did not meet their primary endpoints, they highlighted important biomarker findings

- PMLiVE

Vandria announces positive phase 1 data for Alzheimer’s treatment

Trial data showed that VNA-318 has the ability to penetrate the brain

- PMLiVE

Eisai submits new drug application for subcutaneous Leqembi in Japan

LEQEMBI is a treatment for early Alzheimer’s disease

- PMLiVE

Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

- PMLiVE

Lilly’s early Alzheimer’s disease treatment approved in the EU

Marketing authorisation follows positive late-stage trial results

- PMLiVE

Eli Lilly’s Alzheimer’s disease drug donanemab recommended by CHMP

Up to 6.9 million people in Europe are affected by the neurodegenerative disorder

- PMLiVE

Alnylam’s Amvuttra approved by MHRA to treat rare heart disease ATTR-CM

The drug has been authorised to treat both wild-type and hereditary forms of the disease

- PMLiVE

Alnylam’s Amvuttra granted EC approval to treat rare heart disease ATTR-CM

The RNAi therapeutic has been authorised to treat both wild type and hereditary forms of the disease

- PMLiVE

Alnylam shares phase 3 results for Amvuttra in rare heart disease ATTR-CM

Transthyretin amyloid cardiomyopathy is estimated to affect over 300,000 people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links